Tudor Investment Corp ET AL Raises Stake in OrthoPediatrics Corp. (NASDAQ:KIDS)

Tudor Investment Corp ET AL grew its stake in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 177.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 66,486 shares of the company's stock after purchasing an additional 42,526 shares during the period. Tudor Investment Corp ET AL owned about 0.27% of OrthoPediatrics worth $1,541,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC increased its position in shares of OrthoPediatrics by 319.3% in the third quarter. Barclays PLC now owns 25,298 shares of the company's stock valued at $686,000 after buying an additional 19,264 shares in the last quarter. Dimensional Fund Advisors LP raised its position in OrthoPediatrics by 29.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock worth $15,576,000 after acquiring an additional 152,681 shares during the period. HighTower Advisors LLC purchased a new position in OrthoPediatrics during the fourth quarter valued at $268,000. Charles Schwab Investment Management Inc. increased its stake in shares of OrthoPediatrics by 2.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 136,234 shares of the company's stock worth $3,158,000 after purchasing an additional 3,800 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of OrthoPediatrics by 204.8% during the 4th quarter. JPMorgan Chase & Co. now owns 42,817 shares of the company's stock worth $992,000 after purchasing an additional 28,768 shares during the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

OrthoPediatrics Trading Down 4.5 %

KIDS stock traded down $1.04 during trading on Friday, reaching $22.04. 130,348 shares of the stock were exchanged, compared to its average volume of 196,870. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $535.29 million, a price-to-earnings ratio of -17.92 and a beta of 1.09. The business has a 50 day moving average price of $23.08 and a 200-day moving average price of $24.08. OrthoPediatrics Corp. has a 1 year low of $20.25 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.13). The firm had revenue of $52.41 million for the quarter, compared to analysts' expectations of $51.68 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. On average, research analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Lake Street Capital began coverage on OrthoPediatrics in a research note on Monday, April 7th. They set a "buy" rating and a $37.00 price objective for the company. Stifel Nicolaus decreased their price objective on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Truist Financial dropped their target price on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a report on Friday, April 11th. Piper Sandler lowered their price target on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of OrthoPediatrics in a report on Thursday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, OrthoPediatrics presently has an average rating of "Moderate Buy" and a consensus price target of $35.83.

Insider Transactions at OrthoPediatrics

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the sale, the chief executive officer now directly owns 319,155 shares in the company, valued at $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Fred Hite sold 6,443 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $160,172.98. Following the completion of the sale, the chief financial officer now directly owns 207,989 shares in the company, valued at $5,170,606.54. This trade represents a 3.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,732 shares of company stock worth $589,978. 32.70% of the stock is currently owned by company insiders.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.